25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Zelira Therapeutics Ltd
Buy, Hold or Sell?

Let's analyze Zelira Therapeutics Ltd together

I guess you are interested in Zelira Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Zelira Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Zelira Therapeutics Ltd

I send you an email if I find something interesting about Zelira Therapeutics Ltd.

1. Quick Overview

1.1. Quick analysis of Zelira Therapeutics Ltd (30 sec.)










1.2. What can you expect buying and holding a share of Zelira Therapeutics Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
A$-0.37
Expected worth in 1 year
A$-13.02
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
A$-12.65
Return On Investment
-1,721.1%

For what price can you sell your share?

Current Price per Share
A$0.74
Expected price per share
A$0.67 - A$1.1
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Zelira Therapeutics Ltd (5 min.)




Live pricePrice per Share (EOD)
A$0.74
Intrinsic Value Per Share
A$-6.07 - A$2.15
Total Value Per Share
A$-6.43 - A$1.78

2.2. Growth of Zelira Therapeutics Ltd (5 min.)




Is Zelira Therapeutics Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?-$2.8m$21.3m-$24.2m-859.9%

How much money is Zelira Therapeutics Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$24.6m-$3.7m-$20.9m-84.8%
Net Profit Margin-38,513.0%-1,850.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Zelira Therapeutics Ltd (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Zelira Therapeutics Ltd?

Welcome investor! Zelira Therapeutics Ltd's management wants to use your money to grow the business. In return you get a share of Zelira Therapeutics Ltd.

First you should know what it really means to hold a share of Zelira Therapeutics Ltd. And how you can make/lose money.

Speculation

The Price per Share of Zelira Therapeutics Ltd is A$0.735. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Zelira Therapeutics Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Zelira Therapeutics Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$-0.37. Based on the TTM, the Book Value Change Per Share is A$-3.16 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.35 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Zelira Therapeutics Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-2.17-295.9%-2.17-295.9%-0.33-45.1%-0.83-112.7%-0.49-66.7%
Usd Book Value Change Per Share-2.13-290.3%-2.13-290.3%-0.24-32.2%-0.09-11.8%-0.03-4.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.056.9%
Usd Total Gains Per Share-2.13-290.3%-2.13-290.3%-0.24-32.2%-0.09-11.8%0.023.0%
Usd Price Per Share0.19-0.19-1.02-0.39-0.21-
Price to Earnings Ratio-0.09--0.09--3.07--0.85--0.52-
Price-to-Total Gains Ratio-0.09--0.09--4.31--1.87--1.03-
Price to Book Ratio-0.76--0.76-0.54-0.02-0.04-
Price-to-Total Gains Ratio-0.09--0.09--4.31--1.87--1.03-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.495978
Number of shares2016
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-2.13-0.09
Usd Total Gains Per Share-2.13-0.09
Gains per Quarter (2016 shares)-4,302.19-174.58
Gains per Year (2016 shares)-17,208.76-698.34
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-17209-172190-698-708
20-34418-344280-1397-1406
30-51626-516370-2095-2104
40-68835-688460-2793-2802
50-86044-860550-3492-3500
60-103253-1032640-4190-4198
70-120461-1204730-4888-4896
80-137670-1376820-5587-5594
90-154879-1548910-6285-6292
100-172088-1721000-6983-6990

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%2.018.01.09.5%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%3.07.00.030.0%10.011.00.047.6%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%1.00.09.010.0%3.00.018.014.3%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%3.07.00.030.0%10.011.00.047.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Zelira Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---3.162-3.1620%-0.351-89%-0.128-96%-0.043-99%
Book Value Per Share---0.368-0.3680%2.795-113%2.390-115%1.348-127%
Current Ratio--0.6010.6010%0.940-36%2.612-77%19.856-97%
Debt To Asset Ratio--1.8051.8050%0.064+2708%0.399+352%0.558+224%
Debt To Equity Ratio----0%0.069-100%0.040-100%0.050-100%
Dividend Per Share----0%-0%-0%0.076-100%
Eps---3.223-3.2230%-0.491-85%-1.228-62%-0.726-77%
Free Cash Flow Per Share---0.387-0.3870%-0.639+65%-0.646+67%-0.401+4%
Free Cash Flow To Equity Per Share---0.041-0.0410%-0.483+1079%-0.155+279%-0.032-23%
Gross Profit Margin--1.0001.0000%1.013-1%1.053-5%1.101-9%
Intrinsic Value_10Y_max--2.151--------
Intrinsic Value_10Y_min---6.066--------
Intrinsic Value_1Y_max---0.268--------
Intrinsic Value_1Y_min---0.643--------
Intrinsic Value_3Y_max---0.438--------
Intrinsic Value_3Y_min---1.912--------
Intrinsic Value_5Y_max---0.162--------
Intrinsic Value_5Y_min---3.152--------
Market Cap8340192.000+62%3177216.0003177216.0000%17134272.000-81%6483790.080-51%3482455.680-9%
Net Profit Margin---385.130-385.1300%-18.508-95%-86.971-77%-84.170-78%
Operating Margin---65.011-65.0110%-24.617-62%-24.941-62%-52.998-18%
Operating Ratio--66.01166.0110%25.617+158%25.741+156%54.820+20%
Pb Ratio-1.999-163%-0.761-0.7610%0.540-241%0.024-3326%0.035-2274%
Pe Ratio-0.228-163%-0.087-0.0870%-3.075+3439%-0.845+873%-0.523+502%
Price Per Share0.735+62%0.2800.2800%1.510-81%0.571-51%0.307-9%
Price To Free Cash Flow Ratio-1.900-163%-0.724-0.7240%-2.364+226%-0.880+22%-0.559-23%
Price To Total Gains Ratio-0.232-163%-0.089-0.0890%-4.306+4764%-1.874+2017%-1.026+1059%
Quick Ratio--0.4090.4090%0.077+430%1.876-78%19.453-98%
Return On Assets---7.055-7.0550%-0.164-98%-1.590-77%-2.107-70%
Return On Equity----0%-0.1750%-0.1890%-0.4050%
Total Gains Per Share---3.162-3.1620%-0.351-89%-0.128-96%0.032-9905%
Usd Book Value---2816055.116-2816055.1160%21399122.640-113%18301349.591-115%10323062.193-127%
Usd Book Value Change Per Share---2.134-2.1340%-0.237-89%-0.087-96%-0.029-99%
Usd Book Value Per Share---0.248-0.2480%1.886-113%1.613-115%0.910-127%
Usd Dividend Per Share----0%-0%-0%0.051-100%
Usd Eps---2.175-2.1750%-0.331-85%-0.828-62%-0.490-77%
Usd Free Cash Flow---2961420.532-2961420.5320%-4891677.834+65%-4944087.931+67%-3067909.775+4%
Usd Free Cash Flow Per Share---0.261-0.2610%-0.431+65%-0.436+67%-0.270+4%
Usd Free Cash Flow To Equity Per Share---0.028-0.0280%-0.326+1079%-0.105+279%-0.021-23%
Usd Market Cap5627961.562+62%2143985.3572143985.3570%11562206.746-81%4375261.546-51%2349961.093-9%
Usd Price Per Share0.496+62%0.1890.1890%1.019-81%0.386-51%0.207-9%
Usd Profit---24676696.419-24676696.4190%-3760665.124-85%-9400144.576-62%-5515443.858-78%
Usd Revenue--64073.61064073.6100%203196.451-68%440418.882-85%328355.588-80%
Usd Total Gains Per Share---2.134-2.1340%-0.237-89%-0.087-96%0.022-9905%
 EOD+6 -2MRQTTM+0 -0YOY+10 -235Y+9 -2410Y+8 -27

3.3 Fundamental Score

Let's check the fundamental score of Zelira Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.228
Price to Book Ratio (EOD)Between0-1-1.999
Net Profit Margin (MRQ)Greater than0-385.130
Operating Margin (MRQ)Greater than0-65.011
Quick Ratio (MRQ)Greater than10.409
Current Ratio (MRQ)Greater than10.601
Debt to Asset Ratio (MRQ)Less than11.805
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-7.055
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Zelira Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.880
Ma 20Greater thanMa 500.733
Ma 50Greater thanMa 1000.726
Ma 100Greater thanMa 2000.615
OpenGreater thanClose0.735
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Zelira Therapeutics Ltd

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter products, including SprinJene, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

Fundamental data was last updated by Penke on 2024-09-26 10:42:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Zelira Therapeutics Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of -38,513.0% means that $-385.13 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Zelira Therapeutics Ltd:

  • The MRQ is -38,513.0%. The company is making a huge loss. -2
  • The TTM is -38,513.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-38,513.0%TTM-38,513.0%0.0%
TTM-38,513.0%YOY-1,850.8%-36,662.3%
TTM-38,513.0%5Y-8,697.1%-29,815.9%
5Y-8,697.1%10Y-8,417.0%-280.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-38,513.0%-115.9%-38,397.1%
TTM-38,513.0%-189.7%-38,323.3%
YOY-1,850.8%-205.7%-1,645.1%
5Y-8,697.1%-363.4%-8,333.7%
10Y-8,417.0%-469.8%-7,947.2%
4.3.1.2. Return on Assets

Shows how efficient Zelira Therapeutics Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • -705.5% Return on Assets means that Zelira Therapeutics Ltd generated $-7.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Zelira Therapeutics Ltd:

  • The MRQ is -705.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -705.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-705.5%TTM-705.5%0.0%
TTM-705.5%YOY-16.4%-689.1%
TTM-705.5%5Y-159.0%-546.5%
5Y-159.0%10Y-210.7%+51.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-705.5%-10.9%-694.6%
TTM-705.5%-11.7%-693.8%
YOY-16.4%-11.2%-5.2%
5Y-159.0%-12.9%-146.1%
10Y-210.7%-14.4%-196.3%
4.3.1.3. Return on Equity

Shows how efficient Zelira Therapeutics Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • 0.0% Return on Equity means Zelira Therapeutics Ltd generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Zelira Therapeutics Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-17.5%+17.5%
TTM-5Y-18.9%+18.9%
5Y-18.9%10Y-40.5%+21.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.1%+14.1%
TTM--15.9%+15.9%
YOY-17.5%-13.6%-3.9%
5Y-18.9%-19.0%+0.1%
10Y-40.5%-19.3%-21.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Zelira Therapeutics Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Zelira Therapeutics Ltd is operating .

  • Measures how much profit Zelira Therapeutics Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • An Operating Margin of -6,501.1% means the company generated $-65.01  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Zelira Therapeutics Ltd:

  • The MRQ is -6,501.1%. The company is operating very inefficient. -2
  • The TTM is -6,501.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-6,501.1%TTM-6,501.1%0.0%
TTM-6,501.1%YOY-2,461.7%-4,039.4%
TTM-6,501.1%5Y-2,494.1%-4,007.0%
5Y-2,494.1%10Y-5,299.8%+2,805.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6,501.1%-258.6%-6,242.5%
TTM-6,501.1%-292.1%-6,209.0%
YOY-2,461.7%-222.0%-2,239.7%
5Y-2,494.1%-385.5%-2,108.6%
10Y-5,299.8%-497.6%-4,802.2%
4.3.2.2. Operating Ratio

Measures how efficient Zelira Therapeutics Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 66.01 means that the operating costs are $66.01 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 66.011. The company is inefficient in keeping operating costs low. -1
  • The TTM is 66.011. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ66.011TTM66.0110.000
TTM66.011YOY25.617+40.394
TTM66.0115Y25.741+40.270
5Y25.74110Y54.820-29.079
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ66.0112.649+63.362
TTM66.0113.101+62.910
YOY25.6173.298+22.319
5Y25.7415.011+20.730
10Y54.8206.530+48.290
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Zelira Therapeutics Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Zelira Therapeutics Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.60 means the company has $0.60 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 0.601. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.601. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.601TTM0.6010.000
TTM0.601YOY0.940-0.340
TTM0.6015Y2.612-2.011
5Y2.61210Y19.856-17.244
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6013.793-3.192
TTM0.6014.010-3.409
YOY0.9404.740-3.800
5Y2.6125.980-3.368
10Y19.8566.318+13.538
4.4.3.2. Quick Ratio

Measures if Zelira Therapeutics Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 0.41 means the company can pay off $0.41 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 0.409. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.409. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.409TTM0.4090.000
TTM0.409YOY0.077+0.331
TTM0.4095Y1.876-1.467
5Y1.87610Y19.453-17.578
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4093.349-2.940
TTM0.4093.580-3.171
YOY0.0774.735-4.658
5Y1.8765.922-4.046
10Y19.4536.499+12.954
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Zelira Therapeutics Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Zelira Therapeutics Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Zelira Therapeutics Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.81 means that Zelira Therapeutics Ltd assets are financed with 180.5% credit (debt) and the remaining percentage (100% - 180.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 1.805. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.805. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.805TTM1.8050.000
TTM1.805YOY0.064+1.741
TTM1.8055Y0.399+1.406
5Y0.39910Y0.558-0.159
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8050.340+1.465
TTM1.8050.341+1.464
YOY0.0640.309-0.245
5Y0.3990.365+0.034
10Y0.5580.382+0.176
4.5.4.2. Debt to Equity Ratio

Measures if Zelira Therapeutics Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY0.069-0.069
TTM-5Y0.040-0.040
5Y0.04010Y0.050-0.009
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.393-0.393
TTM-0.437-0.437
YOY0.0690.373-0.304
5Y0.0400.449-0.409
10Y0.0500.489-0.439
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Zelira Therapeutics Ltd generates.

  • Above 15 is considered overpriced but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • A PE ratio of -0.09 means the investor is paying $-0.09 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Zelira Therapeutics Ltd:

  • The EOD is -0.228. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.087. Based on the earnings, the company is expensive. -2
  • The TTM is -0.087. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.228MRQ-0.087-0.141
MRQ-0.087TTM-0.0870.000
TTM-0.087YOY-3.075+2.988
TTM-0.0875Y-0.845+0.759
5Y-0.84510Y-0.523-0.323
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.228-2.319+2.091
MRQ-0.087-2.392+2.305
TTM-0.087-2.926+2.839
YOY-3.075-3.428+0.353
5Y-0.845-5.926+5.081
10Y-0.523-6.207+5.684
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Zelira Therapeutics Ltd:

  • The EOD is -1.900. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.724. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.724. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.900MRQ-0.724-1.176
MRQ-0.724TTM-0.7240.000
TTM-0.724YOY-2.364+1.640
TTM-0.7245Y-0.880+0.156
5Y-0.88010Y-0.559-0.321
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.900-2.989+1.089
MRQ-0.724-3.184+2.460
TTM-0.724-3.470+2.746
YOY-2.364-4.583+2.219
5Y-0.880-8.064+7.184
10Y-0.559-8.680+8.121
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Zelira Therapeutics Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.76 means the investor is paying $-0.76 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Zelira Therapeutics Ltd:

  • The EOD is -1.999. Based on the equity, the company is expensive. -2
  • The MRQ is -0.761. Based on the equity, the company is expensive. -2
  • The TTM is -0.761. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.999MRQ-0.761-1.237
MRQ-0.761TTM-0.7610.000
TTM-0.761YOY0.540-1.302
TTM-0.7615Y0.024-0.785
5Y0.02410Y0.035-0.011
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.9991.968-3.967
MRQ-0.7611.972-2.733
TTM-0.7612.204-2.965
YOY0.5402.370-1.830
5Y0.0243.574-3.550
10Y0.0354.216-4.181
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Zelira Therapeutics Ltd.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-06-302021-06-302022-06-302023-06-302024-06-30
Total Stockholder Equity 34,5473,28337,830-2,62635,203-3,40131,802-36,317-4,515
Long-term Assets Other  -33,848672-33,176614-32,561485-32,07632,731655



5.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. All numbers in thousands.

Summary
Total Assets5,183
Total Liabilities9,357
Total Stockholder Equity-4,515
 As reported
Total Liabilities 9,357
Total Stockholder Equity+ -4,515
Total Assets = 5,183

Assets

Total Assets5,183
Total Current Assets4,260
Long-term Assets923
Total Current Assets
Cash And Cash Equivalents 586
Net Receivables 2,312
Inventory 1,252
Other Current Assets 110
Total Current Assets  (as reported)4,260
Total Current Assets  (calculated)4,260
+/-0
Long-term Assets
Property Plant Equipment 225
Long-term Assets Other 655
Long-term Assets  (as reported)923
Long-term Assets  (calculated)880
+/- 43

Liabilities & Shareholders' Equity

Total Current Liabilities7,093
Long-term Liabilities2,263
Total Stockholder Equity-4,515
Total Current Liabilities
Short-term Debt 3,686
Accounts payable 3,407
Total Current Liabilities  (as reported)7,093
Total Current Liabilities  (calculated)7,093
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)2,263
Long-term Liabilities  (calculated)0
+/- 2,263
Total Stockholder Equity
Common Stock45,516
Retained Earnings -81,336
Accumulated Other Comprehensive Income 31,305
Total Stockholder Equity (as reported)-4,515
Total Stockholder Equity (calculated)-4,515
+/-0
Other
Cash and Short Term Investments 586
Common Stock Shares Outstanding 11,347
Liabilities and Stockholders Equity 5,183
Net Debt 3,249
Net Working Capital -2,833
Short Long Term Debt Total 3,836



5.3. Balance Sheets Structured

All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-30
> Total Assets 
8,542
10,023
26,451
9,272
1,399
3,547
695
875
1,431
1,078
780
408
88
7,967
6,314
3,515
35,789
39,366
37,701
33,891
5,183
5,18333,89137,70139,36635,7893,5156,3147,967884087801,0781,4318756953,5471,3999,27226,45110,0238,542
   > Total Current Assets 
2,512
1,790
8,618
9,272
1,125
3,453
430
805
1,347
973
599
333
88
7,967
5,777
3,125
1,833
6,090
5,076
1,771
4,260
4,2601,7715,0766,0901,8333,1255,7777,967883335999731,3478054303,4531,1259,2728,6181,7902,512
       Cash And Cash Equivalents 
2,152
1,460
1,962
229
1,094
2,708
343
788
1,279
969
598
325
56
7,868
5,686
3,073
1,697
4,971
2,746
146
586
5861462,7464,9711,6973,0735,6867,868563255989691,2797883432,7081,0942291,9621,4602,152
       Short-term Investments 
0
0
5,375
0
0
619
0
0
0
0
0
0
0
0
0
0
-108
-100
0
0
0
000-100-1080000000000619005,37500
       Net Receivables 
110
80
709
1,108
29
123
87
17
69
4
2
9
32
95
67
33
63
57
256
-1
2,312
2,312-1256576333679532924691787123291,10870980110
       Inventory 
250
250
365
4,259
1
1
0
0
0
0
0
0
-39
-95
-67
-33
-64
868
1,957
1,528
1,252
1,2521,5281,957868-64-33-67-95-39000000114,259365250250
   > Long-term Assets 
6,030
8,233
17,833
0
274
94
265
70
84
105
181
75
0
0
537
391
33,956
33,275
32,625
32,120
923
92332,12032,62533,27533,9563915370075181105847026594274017,8338,2336,030
       Property Plant Equipment 
4,974
7,177
17,811
0
274
94
68
70
84
105
181
75
0
0
0
33
1,580
1,239
848
519
225
2255198481,2391,580330007518110584706894274017,8117,1774,974
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,747
30,747
30,747
30,747
30,747
0
030,74730,74730,74730,74730,747000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
537
358
350
167
64
43
0
0436416735035853700000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,026
32,026
31,870
31,714
31,558
0
031,55831,71431,87032,02632,026000000000000000
       Other Assets 
1,056
1,056
21
0
0
0
0
0
0
0
0
58
0
0
0
0
108
100
0
0
0
00010010800005800000000211,0561,056
> Total Liabilities 
252
143
11,576
24,116
123
1,069
41
214
79
38
30
50
290
71
99
407
1,242
1,536
2,011
2,179
9,357
9,3572,1792,0111,5361,242407997129050303879214411,06912324,11611,576143252
   > Total Current Liabilities 
252
143
8,030
24,116
123
271
41
214
79
38
30
50
290
71
99
407
670
1,076
1,627
1,884
7,093
7,0931,8841,6271,0766704079971290503038792144127112324,1168,030143252
       Short-term Debt 
0
0
2,848
3,317
0
0
0
0
0
0
0
0
1,000
0
0
61
61
91
117
143
3,686
3,686143117916161001,000000000003,3172,84800
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
1,000
0
0
0
0
0
0
0
0
000000001,000000000000000
       Accounts payable 
57
59
2,692
18,646
98
212
41
214
79
38
30
50
45
71
99
407
559
985
1,510
1,741
3,407
3,4071,7411,51098555940799714550303879214412129818,6462,6925957
       Other Current Liabilities 
195
84
1,420
1,911
25
59
0
214
79
38
30
50
246
0
0
50
50
91
117
143
0
01431179150500024650303879214059251,9111,42084195
   > Long-term Liabilities 
0
0
3,546
0
0
798
0
0
0
0
0
0
0
0
0
571
571
461
384
295
2,263
2,263295384461571571000000000798003,54600
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
571
461
384
295
0
02953844615710000000000000000
       Other Liabilities 
0
0
3,262
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000003,26200
> Total Stockholder Equity
8,290
9,879
14,875
-14,843
1,276
2,478
654
661
1,352
1,040
750
358
-203
7,897
6,214
3,108
34,547
37,830
35,203
31,802
-4,515
-4,51531,80235,20337,83034,5473,1086,2147,897-2033587501,0401,3526616542,4781,276-14,84314,8759,8798,290
   Common Stock
8,402
10,303
14,428
24,820
28,325
14,947
14,947
14,947
15,962
15,962
15,962
15,970
16,308
13,803
13,823
13,823
26,076
36,651
43,746
45,516
45,516
45,51645,51643,74636,65126,07613,82313,82313,80316,30815,97015,96215,96215,96214,94714,94714,94728,32524,82014,42810,3038,402
   Retained Earnings -81,336-44,767-39,194-27,249-18,700-11,680-8,112-6,382-16,510-15,612-15,526-19,141-18,829-18,191-18,198-20,736-27,048-39,663-1,501-424-112
   Capital Surplus 000000000000000000000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
4,219
314
0
0
475
503
965
27,171
28,427
30,651
-570
0
0-57030,65128,42727,171965503475003144,219000000000



5.4. Balance Sheets

All numbers in thousands.




5.5. Cash Flows

All numbers in thousands.